Physician profile
Marcus Magnet
NPI 1740249457
$11,587.37
in general payments reported to CMS, 2019-2025
52 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $1,468 · 2021: $1,578 · 2022: $1,787 · 2023: $1,902 · 2024: $1,843 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,517.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,489.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,410.90 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,205.30 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $994.30 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $942.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $658.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $548.47 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $403.44 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Teva Pharmaceuticals USA, INC. | $311.34 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astellas Pharma US INC | $281.45 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $280.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.72 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $251.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $234.52 | 2019-2025 | Rexulti, Abilify Mycite |
| Janssen Pharmaceuticals, INC | $232.64 | 2019-2025 | Spravato |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Magnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.